Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunotherapy |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA45
|
| gptkbp:brand |
Zeposia
|
| gptkbp:CASNumber |
1306760-87-1
|
| gptkbp:chemicalFormula |
C23H24N4O3
|
| gptkbp:developer |
gptkb:Celgene
gptkb:Bristol_Myers_Squibb Receptos |
| gptkbp:drugClass |
sphingosine-1-phosphate receptor modulator
|
| gptkbp:eliminationHalfLife |
19 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
ozanimod
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
S1P receptor modulator
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
404.46 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
hypertension elevated liver enzymes upper respiratory tract infection |
| gptkbp:target |
gptkb:S1PR1
gptkb:S1PR5 |
| gptkbp:usedFor |
multiple sclerosis
ulcerative colitis |
| gptkbp:bfsParent |
gptkb:sphingosine-1-phosphate_receptor_1
gptkb:L04AC14 |
| gptkbp:bfsLayer |
7
|